| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ea343511fc62b3f38d3dabbdba062a1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001151 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2002-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f9f0c7102f1aabaa8ef9fdb6797f288
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d03202c29d33ce32170aefaabf573a75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e83fda5a6f041953852fe4babf60c49c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0add6cd48ca067502fa6297241ccbb84 |
| publicationDate |
2003-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003045499-A1 |
| titleOfInvention |
Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses |
| abstract |
The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is intradermally administered to said hyperproliferative cells. In another embodiment of the present invention, a pathogen-induced disease in which the pathogen gene expression is increased or altered, is treated by intradermally administered a pathogen gene under the control of a promoter operable in eukaryotic cells. The present invention thus provides immunotherapies for treating hyperproliferative and pathogen diseases by attenuating the natural immune systems CTL response against hyperproliferative cells or overexpressing mutant p53 antigens. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11414457-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11548924-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009204071-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007054378-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006066229-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10221224-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006066229-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005208627-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8672879-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10815274-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10815273-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10100087-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9919037-B2 |
| priorityDate |
1999-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |